Fixed Duration of Venetoclax-Rituximab for CLL May Prolong Survival

When used as a fixed-duration venetoclax-rituximab combination, 62% of patients achieved an undetectable minimal residual disease level in peripheral blood.

from Latest articles from Cancer Therapy Advisor Hematologic Cancers https://ift.tt/2QG21EX